latest news releases from the newsroom
Integra LifeSciences Holdings Corporation
Integra LifeSciences Announces Theken Products Will be Marketed as Integra Spine
PLAINSBORO, N.J., Oct. 14, 2008 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq:IART) announced today that the Theken products will now be marketed under the name Integra Spine(TM), and will be featured at the upcoming North American Spine Society annual meeting, October 15-17, 2008, in Toronto, Canada. The transition to Integra Spine will align the spinal implant business more closely with the Integra corporate brand.
Alphatec Holdings, Inc.
Alphatec Spine Launches www.agingspinecenter.com -- Web-Based Portal for Healthcare Providers and Patients
CARLSBAD, Calif., Oct. 14, 2008 (GLOBE NEWSWIRE) -- Alphatec Holdings, Inc. (Nasdaq:ATEC), the parent company of Alphatec Spine, Inc., a leading medical technology company that designs, develops, manufactures and markets products for the surgical treatment of spine disorders, with a focus on treating conditions affecting the aging spine, announced today that it has launched www.agingspinecenter.com, a web-based information portal for healthcare providers and patients regarding aging spine disorders and their treatment.
3D Systems Corporation
3D Systems Launches Second Wax Pattern Printer
ROCK HILL, S.C., Oct. 14, 2008 (GLOBE NEWSWIRE) -- 3D Systems Corporation (Nasdaq:TDSC), a leading provider of 3-D Printing, Rapid Prototyping and Manufacturing solutions, announced today the ProJet(tm) CP 3000 3-D Production System for the high-speed, high-volume production of RealWax(tm) casting patterns from digital data for foundry prototyping and end-use parts applications.
Promius Pharma, LLC Launches EpiCeram(R) Skin Barrier Emulsion
DENVER, Oct 14, 2008 -- Ceragenix Pharmaceuticals, Inc., (OTCBB:CGXP) today announced that Promius Pharma, LLC, a wholly owned subsidiary of Dr. Reddy's Laboratories (NYSE:RDY) ("DRL") launched its first product, EpiCeram(R) Skin Barrier Emulsion. EpiCeram Emulsion is a novel prescription therapy for the treatment of atopic dermatitis, a skin disease that affects more than 15 million Americans at an estimated cost of $1 billion annually. Promius Pharma launched EpiCeram Emulsion this week at the 27th Annual Fall Clinical Dermatology Conference, attended by over 400 dermatologists and healthcare providers.
Infinity Pharmaceuticals, Inc.
Infinity to Present New Data On Its Innovative Anti-Cancer Agents At AACR-EORTC-NCI Symposium
CAMBRIDGE, Mass., Oct. 14, 2008 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI), an innovative cancer drug discovery and development company, today announced that new data from several preclinical studies evaluating the company's innovative small molecule drug candidates -- oral Hsp90 inhibitor IPI-493 and oral Hedgehog signaling pathway inhibitor IPI-926 -- will be presented during the 20th AACR-EORTC-NCI Symposium on "Molecular Targets and Cancer Therapeutics," being held in Geneva, Switzerland from October 21 through October 24, 2008.
BSD Medical Corporation
Dr. Michael Nobel Delivers Keynote Address On Hyperthermia Therapy At Japanese Cancer Symposium
SALT LAKE CITY, Oct. 14, 2008 (GLOBE NEWSWIRE) -- BSD Medical Corporation (Nasdaq:BSDM) announced today that a member of its Board of Directors, Dr. Michael Nobel, was the keynote speaker at the Japanese Cancer Symposium recently concluded at the Shizuoka Cancer Center in Shizuoka, Japan. The symposium addressed the theme, "Fulfilling the Promise of Personalized Medicine in Cancer Therapy: Development of the Medical Engineering Platform."